Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 3, 2012, Pages 357-371

  Mauskopf, Josephine ^a   Talbird, Sandra ^a   Standaert, Baudouin ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b GSK   (Belgium)

Author keywords

cost effectiveness; dynamic transmission model; methods; vaccine program

Indexed keywords

HELICOBACTER PYLORI VACCINE; HEPATITIS A VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH PROGRAM; HELICOBACTER INFECTION; HEPATITIS A; HERPES ZOSTER; HUMAN; INFLUENZA; MEASLES; MENINGOCOCCOSIS; PERTUSSIS; POLIOMYELITIS; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; ROTAVIRUS INFECTION; SENSITIVITY ANALYSIS; STEADY STATE; SYSTEMATIC REVIEW; VACCINATION; VERRUCA VULGARIS;

COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; IMMUNIZATION PROGRAMS; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); TIME FACTORS; VACCINATION;

EID: 84864198709     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.11     Document Type: Review

References (61)

1. Cost-Effectiveness in Health and Medicine Gold MR, Siegel JE, Russell LB, Weinstein MC. Oxford University Press, NY, USA (1996
2. Bauch CT, Anonychuk AM, Van Effelterre T, Pham BZ, Merid MF. Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness. Med. Decis. Making 29(5), 557-569 (2009
3. Soárez PC, Novaes HM, Sartori AM. Impact of methodology on the results of economic evaluations of varicella vaccination programs: Is it important for decision-making? Cad. Saude. Publica 25(Suppl. 3), S401-S414 (2009
4. Beutels P, Van Doorslaer E, Van Damme P, Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev. Vaccines 2(5), 649-660 (2003
5. Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine 25(32), 5945-5957 (2007
6. Bos JM, Alphen L, Postma MJ. The use of modeling in the economic evaluation of vaccines. Expert Rev. Pharmacoecon. Outcomes Res. 2(5), 443-455 (2002
7. Ferko N, Postma M, GalliVan S, Kruzikas D, Drummond M. Evolution of the health economics of cervical cancer vaccination. Vaccine 26(Suppl. 5), F3-F15 (2008
8. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: A focused review of modelling approaches. Pharmacoeconomics 26(3), 191-215 (2008
9. Boily MC, Abu-Raddad L, Desai K, Masse B, Self S, Anderson R. Measuring the public-health impact of candidate HIV vaccines as part of the licensing process. Lancet Infect. Dis. 8(3), 200-207 (2008
10. Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 28(11), 2356-2359 (2010)
11. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: The impact of herd-immunity. Med. Decis. Making 23(1), 76-82 (2003
12. Dasbach EJ, Elbasha EH, Insinga RP Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus nfection and disease. Epidemiol. Rev. 28, 88-100 (2006
13. Jeurissen S, Makar A. Epidemiological and economic impact of human papillomavirus vaccines. Int. J. Gynecol. Cancer 19(4), 761-771 (2009
14. Kauf TL. Methodological concerns with economic evaluations of meningococcal vaccines. Pharmacoeconomics 28(6), 449-461 (2010
15. Lugnér AK, Mylius SD, Wallinga J. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Econ. 19(5), 518-531 (2010
16. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: A systematic review. Pharmacoeconomics 27(2), 127-147 (2009
17. Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med. Decis. Making 26(5), 434-446 (2006
18. Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 25(51), 8536-8548 (2007
19. Baguelin M, Hoek AJ, Jit M, Flasche S, White PJ, Edmunds WJ. Vaccination against pandemic influenza A/H1N1v in England: A real-time economic evaluation. Vaccine 28(12), 2370-2384 (2010
20. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1)2009. Ann. Intern. Med. 151(12), 829-839 (2009
21. Khazeni N, Hutton DW, Garber AM, Owens DK. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuVanted vaccination strategies for an influenza A (H5N1) pandemic. Ann. Intern. Med. 151(12), 840-853 (2009
22. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337, a769 (2008
23. Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 26(44), 5654-5661 (2008
24. Coudeville L, Brunot A, Giaquinto C, Lucioni C, Dervaux B. Varicella vaccination in Italy: An economic evaluation of different scenarios. Pharmacoeconomics 22(13), 839-855 (2004
25. Lenne X, Diez Domingo J, Gil A, Ridao M, Lluch JA, Dervaux B. Economic evaluation of varicella vaccination in Spain: Results from a dynamic model. Vaccine 24(47-48), 6980-6989 (2006
26. Levin A, Burgess C, Garrison LP Jr et al Global eradication of measles: An epidemiologic and economic evaluation. J. Infect. Dis. 204(Suppl. 1), S98-S106 (2011
27. Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20(9-10), 1316-1330 (2002
28. Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: Cost-utility analysis. Arch. Dis. Child 88(10), 862-869 (2003
29. Pradas-Velasco R, Antoñanzas-Villar F, Martínez- Zárate MP. Dynamic modelling of infectious diseases: An application to the economic evaluation of influenza vaccination. Pharmacoeconomics 26(1), 45-56 (2008
30. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18)in the UK. BJOG 115(8), 947-956 (2008
31. Dasbach EJ, Largeron N, Elbasha EH. Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev. Pharmacoecon. Outcomes Res. 8(5), 491-500 (2008
32. Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pac. J. Cancer Prev. 9(3), 459-466 (2008
33. Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH. The cost-effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18)in Hungary. J. Med. Econ. 13(1), 110-118 (2010
34. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human papillomavirus (HPV)vaccination in Mexico: A transmission dynamic model-based evaluation. Vaccine 26(1), 128-139 (2007
35. Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int. J. Technol. Assess. Health Care 26(2), 183-191 (2010
36. Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirusvaccination programs to prevent cervical cancer in Austria. Vaccine 27(37), 5133-5141 (2009
37. Valentim J, Sartori AM, de Soárez PC, Amaku M, Azevedo RS, Novaes HM Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. Vaccine 26(49), 6281-6291 (2008
38. Shim E, GalVani AP. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 27(30), 4025-4030 (2009
39. Rupnow MF, Chang AH, Shachter RD, Owens DK, Parsonnet J. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J. Infect. Dis. 200(8), 1311-1317 (2009
40. Sander B, Nizam A, Garrison LP Jr, Postma MJ, Halloran ME, Longini IM Jr. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health 12(2), 226-233 (2009
41. Perlroth DJ, Glass RJ, Davey VJ, Cannon D, Garber AM, Owens DK. Health outcomes and costs of community mitigation strategies for an influenza pandemic in the United States. Clin. Infect. Dis. 50(2), 165-174 (2010
42. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 20(7-8), 1113-1125 (2002)
43. Banz K, Wagenpfeil S, Neiss A et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 21(11-12), 1256-1267 (2003
44. Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Health 8(3), 209-222 (2005
45. de Vries R, Kretzschmar M, Schellekens JF et al. Cost-effectiveness of adolescent pertussis vaccination for The Netherlands: Using an individual-based dynamic model. PLoS ONE 5(10), e13392 (2010
46. Stevenson M, Beard S, Finn A, Brennan A. Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule Vaccine 20(13-14), 1778-1786 (2002
47. Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: Results of a dynamic health-economic analysis. J. Gastroenterol. 42(2), 152-160 (2007
48. Thompson KM, Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal 26(6), 1423-1440 (2006
49. Beutels P, Gay NJ. Economic evaluation of options for measles vaccination strategy in a hypothetical western European country. Epidemiol. Infect. 130(2), 273-283 (2003
50. Bishai D, Johns B, Nair D et al. The cost-effectiveness of supplementary immunization activities for measles: A stochastic model for Uganda. J. Infect. Dis. 204(Suppl. 1), S107-S115 (2011
51. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis. 13(1), 28-41 (2007
52. Babigumira JB, Levin A, Burgess C et al. Assessing the cost-effectiveness of measles elimination in Uganda: Local impact of a global eradication program. J. Infect. Dis. 204(Suppl. 1), S116-S123 (2011
53. Coudeville L, Van Rie A, Getsios D, Caro JJ, Crépey P, Nguyen VH. Adult vaccination strategies for the control of pertussis in the United States: An economic evaluation including the dynamic population effects. PLoS ONE 4(7), e6284 (2009
54. De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH. Vaccinating adolescents against meningococcal disease in Canada: A cost-effectiveness analysis. Vaccine 25(29), 5433-5440 (2007)
55. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 359(8), 821-832 (2008
56. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339, b3884 (2009
57. Taira AV, Neukermans CP, Sanders GD Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis. 10(11), 1915-1923 (2004
58. Trotter CL, Edmunds WJ. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC)vaccines using a transmission dynamic model. Med. Decis. Making 26(1), 38-47 (2006
59. Goldie SJ, Kim JJ, Kobus K et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 25(33), 6257-6270 (2007
60. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: A cost-effectiveness analysis in a low-resource setting. Br. J. Cancer 97(9), 1322-1328 (2007
61. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: A dynamic perspective. Stat. Med 18(23), 3263-3282 (1999)